Which class is used for treatment and management of asthma and includes leukotriene receptor antagonist blockers?

Which class is used for treatment and management of asthma and includes leukotriene receptor antagonist blockers?

• A. Beta-agonist
• B. Corticosteroid
• C. Leukotriene receptor antagonist blocker
• D. Phosphodiesterase inhibitor

Answer: (C)

The main idea is targeting a specific inflammatory pathway in asthma. Leukotrienes are mediators that promote bronchoconstriction, mucus production, and airway swelling. Blocking the receptors for these leukotrienes with leukotriene receptor antagonists prevents that chain of events, helping to reduce airway narrowing and inflammation as part of long-term, controller therapy. Drugs in this class, such as montelukast, zafirlukast, and pranlukast, are often taken orally and can be used as an add-on to inhaled corticosteroids or for mild persistent asthma and exercise-induced bronchoconstriction. The other options describe different approaches: beta-agonists provide quick relief by relaxing airway smooth muscle; corticosteroids address broader airway inflammation but do not specifically block leukotriene receptors; phosphodiesterase inhibitors are older, less commonly used agents with broader effects.

The main idea is targeting a specific inflammatory pathway in asthma. Leukotrienes are mediators that promote bronchoconstriction, mucus production, and airway swelling. Blocking the receptors for these leukotrienes with leukotriene receptor antagonists prevents that chain of events, helping to reduce airway narrowing and inflammation as part of long-term, controller therapy. Drugs in this class, such as montelukast, zafirlukast, and pranlukast, are often taken orally and can be used as an add-on to inhaled corticosteroids or for mild persistent asthma and exercise-induced bronchoconstriction. The other options describe different approaches: beta-agonists provide quick relief by relaxing airway smooth muscle; corticosteroids address broader airway inflammation but do not specifically block leukotriene receptors; phosphodiesterase inhibitors are older, less commonly used agents with broader effects.